Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,815.00-0.17%ETH$2,283.98+0.72%GOLD$3,912.50+0.35%OIL$99.46-4.48%
Smart Investors Daily
SID Premium
AG

NASDAQ · AGEN

Agenus Inc.

Healthcare · Biotechnology

$6.84

Down-$0.25 (-3.53%)

Updated Nov 2, 2026, 12:09 PM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
113.25M
P/E ratio
-3.02
Dividend yield
0.00%
52-week range
$2.85 – $10.31
Volume
564.49K
Avg. volume
654.19K

Price performance · AGEN

AGEN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

AGEN closed at $6.84 after 20 trading sessions, down 21.65% for the selected period.

Last close
$6.84
Period change
-21.65%
Period low
$6.04
Period high
$8.73
Daily close
View OHLC price history
AGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$6.87$7.09$6.69$6.84564.49K
Oct 29, 2026$7.13$7.30$6.942$7.09625.39K
Oct 28, 2026$6.51$7.14$6.47$7.13744.3K
Oct 27, 2026$6.13$6.675$6.11$6.65839.02K
Oct 26, 2026$6.49$6.50$6.14$6.16687.89K
Oct 23, 2026$6.36$6.50$6.16$6.33510.51K
Oct 22, 2026$6.32$6.53$6.2364$6.51553.95K
Oct 21, 2026$6.43$6.54$6.31$6.40789.68K
Oct 20, 2026$6.10$6.58$6.05$6.42827.18K
Oct 19, 2026$6.13$6.30$6.055$6.18734.96K
Oct 16, 2026$6.65$6.70$6.00$6.041.03M
Oct 15, 2026$6.52$6.99$6.51$6.68815.43K
Oct 14, 2026$6.88$7.14$6.46$6.50980.14K
Oct 13, 2026$7.30$7.34$6.805$6.95995.56K
Oct 12, 2026$7.625$7.66$7.39$7.43572.49K
Oct 9, 2026$7.495$7.7932$7.38$7.67710.29K
Oct 8, 2026$7.565$7.66$7.24$7.541.22M
Oct 7, 2026$7.28$7.62$7.27$7.571.16M
Oct 6, 2026$8.49$8.49$7.47$7.491.53M
Oct 5, 2026$8.54$8.76$8.1101$8.73956.3K

Latest AGEN news

The latest Smart Investors Daily articles mentioning AGEN.

Stock researchCompany · Overview

AGEN research

Overview

Company profile and research snapshot.

Company profile

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.33
Implied upside
—
Analysts
9
AGEN recent ratings
DateFirmRatingTarget
Oct 26, 2026Chardan CapitalBuy—
Oct 22, 2026Chardan CapitalBuy—
Oct 5, 2026Chardan CapitalBuy—
Sep 28, 2026Rodman & RenshawBuy—
Sep 18, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 25, 2026

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

LEXINGTON, Mass., October 25, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, given before surgery

Yahoo · Oct 20, 2026

Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial

Agenus (NASDAQ:AGEN) is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after ending funding for its BATTMAN study in later-line metastatic disease. Zack Armen, Agenus’ vice preside

Yahoo · Oct 9, 2026

Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference

LEXINGTON, Mass., October 09, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan’s 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation, on October 20, 2026.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By